Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gantenerumab - Roche

Drug Profile

Gantenerumab - Roche

Alternative Names: R-1450; RG-1450; RO-4909832

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Chugai Pharmaceutical; Roche; Washington University School of Medicine
  • Class Antidementias; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 16 Jul 2023 Pooled efficacy and pharmacokinetics data from the phase III GRADUATE-I, GRADUATE-II, SCarlet RoAD and Marguerite RoAD trial in early Alzheimer's disease presented at Alzheimer's Association International Conference (AAIC-2023)
  • 22 Apr 2023 Pooled efficacy and safety data from pharmacokinetic phase I and phase II trials in Healthy volunteers at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)
  • 22 Apr 2023 Pooled efficacy data from the phase III GRADUATE-1 and GRADUATE-2 trial in early Alzheimer's disease presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top